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Figure 2. Modiﬁed Mankin’s Score.
Figure 3. Number of chondrocytes.
Results: Degeneration of the articular cartilage was observed in the
three areas in both groups, but the change in each area was different.
Histological grading scores in the hyaluronan group were smaller at 12
and 16 weeks compared with that in the saline group (Figure 1, 2). The
thickness of the articular cartilage in the non-contact and contact areas
was unchanged, but it was increased in the transitional area in both
groups. The number of chondrocytes in the contact and transitional areas
was decreased in both groups, but the number in the hyaluronan group
was greater at 12 and 16 weeks compared with that in the saline group
(Figure 3).
Conclusions: HA has chondroprotective effects on the articular cartilage
in a rat immobilized knee model, especially for the number of chondro-
cytes. This result may be due to anti-apoptotic effects of HA on the
articular cartilage.
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PROGRESSIVE RADIOGRAPHIC INTERPHALANGEAL
OSTEOARTHRITIS (OA)
M. Gu¨ler-Yu¨ksel1, M. Kloppenburg1, C.F. Allaart1, I. Watt1,
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Purpose: To investigate the association between inﬂammation and the
incidence and progression of interphalangeal OA and the effect of IFX on
interphalangeal OA.
Methods: Data from patients from the BeSt study with X-rays available
were utilized. In the BeSt study 508 recent-onset rheumatoid arthritis
(RA) patients were randomized into 4 treatment strategies: 1. sequential
monotherapy, 2. step-up combination therapy, 3. combination therapy with
prednisone and 4. IFX and methotrexate (MTX). In groups 1−3, patients
proceeded to treatment with IFX and MTX after failing on at least 3 pre-
vious DMARDs. The IFX dose varied between 3 and 10mg/kg/8 weeks.
X-rays of the hands were scored random in time for osteophytes (grade
0−3 for each joint) using the Osteoarthritis Research Society International
atlas in 10 DIP joints (DIPJs) and 8 PIP joints (PIPJs) at baseline and after
3 years. The incidence and progression of OA was deﬁned as a change
from baseline in the osteophyte score greater than SDC (1.7 units) in
patients without and with one or more osteophytes at baseline. Erosions
were measured according to the Sharp-van der Heijde score.
In multivariate analyses, adjusted for age, gender, postmenopausal status
and BMI, associations between the components of the DAS and erosion
scores and the incidence and progression of interphalangeal OA was
determined.
Results: 416 patients (67% women, mean age 54 years) were included.
At baseline, osteophytes were present in 37% of the patients in one
or more DIPJs and in 13% of the patients in one or more PIPJs. After
3 years, 6 and 4% of the patients had incident OA in the DIPJs and PIPJs.
Radiographic progression was present in 18 and 15% of the patients in
the DIPJs and PIPJs. Number of swollen joints at baseline, erosion score
at baseline, change in erosion score after 3 years and postmenopausal
status were associated with incidence of interphalangeal OA. Change
in erosion scores after 3 years was associated with progression of
interphalangeal OA.
178 (43%) patients were treated with IFX during some period of the study
and these patients had less incident OA (4% in patients who received
IFX versus 7% in patients who did not receive IFX, p = 0.211) and less
progressive OA (10 versus 38%, p = 0.020) in the PIPJs. Combination
therapy with IFX did not affect the incidence of OA (7 versus 7%,
p = 0.974), nor the progression (29 versus 24%, p = 0.516) in the DIPJs.
Conclusions: The incidence and progression of interphalangeal OA was
associated with more inﬂammatory activity in RA patients, suggesting that
inﬂammation might play a role in the pathogenesis of interphalangeal OA.
Combination therapy with inﬂiximab reduced the progression of OA in the
PIPJs in the period of three years after baseline, suggesting that anti-TNF
might be an effective treatment against hand OA.
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Purpose: Clinical reports showed that intra-articular treatment with
Hyaluronic products is safe and effective for treatment of Knee os-
teoarthritis (OA). Similar results appeared in some reports about treat-
ment of hip OA, but data are scarce due to the difﬁculties associated
with the injection technique which requires use of X-ray or ultrasound
(US) guidance. We report from the Italian national database of ANTIAGE
(National Association for Ultrasound Guided Intra-articular Treatment of
Hip) about reduction of NSAID intake after intra-articular injection with
hyaluronic products in patient with hip OA.
Methods: 1887 adults, ambulatory patients with hip OA, selected from
February 2004 to April 2008, underwent to intrarticular injections, per-
formed with US guidance, according to Migliore-Tormenta technique.
Every six months patients were injected with several products, Low and
High MW, like Hylan GF-20 (2ml), Hyalgan (4ml), Hyalubrix, (4ml) and
Jointex (4ml). Monthly NSAID intake, by measuring the number of days
the patient had used NSAID during the previous month, was evaluated
at baseline and every three months. Follow-up period was of 42 months.
A multivariate analysis with Wilcoxon test was performed.
Figure 1. NSAID consumption. p< 0.001 for every value obtained at
follow-up when compared with baseline value.
Results: 1887 patients were injected. We found a statistical reduction
of NSAID already after the ﬁrst injection (p< 0.001), decreasing from
7.37 days per patient at baseline to 3.84 after 6 months from the ﬁrst
injection (Fig. 1). The reduction in NSAID consumption obtained was
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still present for the patients that were under therapy after 42 months.
All scores obtained at followup visits showed statistical signiﬁcance
(p< 0.001) when compared with scores obtained at baseline.
Conclusions: Our data suggest that hip viscosupplementation may be
an effective and cost-saving treatment for both patients and Healthcare
system, not only because the spending for NSAID is lowered (direct
costs), but also because gastrointestinal and cardiovascular side effects
commonly associated with NSAID may be reduced (indirect costs).
539 THE EFFECT OF TETRACYCLINES ON HUMAN ARTICULAR
CARTILAGE METABOLISM ARE DEPENDENT ON THE
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Purpose: In search for potential new therapies in the treatment of
osteoarthritis (OA), attention has focused also on tetracyclines and their
ability to slow down the progression of OA. Several possible mechanisms
have been proposed, including inhibition of the activity and expression
of inducible nitric oxide synthase (iNOS) and matrix metalloproteinases
(MMPs). Using normal bovine articular cartilage, minocycline were found
to have a stronger inhibitory effect on e.g. the expression of iNOS and
MMP-1 than doxycycline.
In this line, the purpose of this in vitro study was to determine system-
atically whether tetracyclines (1) inﬂuences the synthesis and release of
PGs, MMPs and PGE2 also from human OA cartilage, (2) are affected by
the degree of OA alterations, (3) are different with respect to their individ-
ual ability to modulate cartilage metabolism, and (4) affect chondrocyte
viability within human OA cartilage explants.
Methods: Full-thickness cartilage explants of the lateral compartment of
the femoral condyles were taken from OA patients undergoing knee re-
placement surgery. 4-mm-diameter articular cartilage discs were obtained
using a biopsy punch. The degree of OA changes of the femoral condyles
was determined according to Collins. Explants from mild (Collins grade
0−1.5) or moderately (Collins grade >1.5−3) affected human OA condyles
were cultured separately in supplemented Ham’s F12 media with media
changes every 3−4 days. Explants were treated with 1, 10, 50 or 100 mM
minocycline, doxycycline or tetracycline in the presence or absence of rec.
human Il-1b (5 ng/ml). PG synthesis was determined by the incorporation
of 35SO4 during the ﬁnal 18 h of the 11 days experiments whereas the
content of PGs were quantitated with the DMMB-assay. The viability of
chondrocytes was assessed microscopically using ﬂuorescein diacetate
and propidium iodide. Nitrite levels in media were measured by using the
Griess reaction. MMP-1, -8, and -13 as well as PGE2 were determined
in media with ELISAs. Results were compared to untreated explants
removed from the same joint. Each experimental condition was repeated
ﬁve times using explants always obtained from 6 different patients (N=6).
Results: The degree of OA alterations of explants can have a profound
modulatory effect on the inﬂuence of tetracylines on cartilage metabolism.
Furthermore, doxycycline partly displayed a weaker pharmacological
effect than minocycline, whereas tetracycline was found to have the
lowest potential to change cartilage metabolism. The viability of explants
was not affected by any of the drugs tested.
Conclusions: Our study indicate that the pharmacological efﬁcacy of
tetracyclines can be dependent on the clinical stage of OA. In addition,
our ﬁndings indicate that minocycline possess a stronger potential than
doxycycline to slow down cartilage destruction during OA.
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Purpose: To investigate the efﬁcacy of the anabolic agent ﬁbroblast
growth factor 18 (rhFGF18; AS902330) in counteracting structural dam-
age and functional impairment in a dog anterior cruciate ligament (ACL)
model of osteoarthritis (OA) over 26 weeks.
Methods: From week 4 after surgical section of the right ACL in mongrel
dogs, intra-articular injections of AS902330 3mg, 10mg or 30mg per joint
(n = 8/dose group) or placebo (saline; n = 8) were given into the OA knee
once a week for 3 consecutive weeks. The animals were followed up
through week 26. Peak vertical force (PVF) was recorded at baseline
and at weeks 4, 8, 14, 20 and 26. MRI of the stiﬂe joint was performed
at weeks 4, 8 and 26. Semi-quantitative scores were determined for
osteophytosis, bone marrow lesions and cartilage defects, and cartilage
volume was measured. Macroscopic measurements of cartilage lesions
(condyles and plateaus) were performed at weeks 8 (3 dogs/group) and
26 (5 dogs/group). Exposure was determined using high performance
ELISA. All injections were undertaken and evaluations performed by
investigators blinded to the assigned treatment.
Results: Following section of the ACL, all dogs developed functional
impairment, but there was less loss of PVF in dogs treated with any of
the tested doses of AS902330 than in controls. In placebo-treated dogs,
the evolution of structural damage over time (weeks 4−26) correlated
with worsening limb function as expressed by PVF. As early as week 8
(i.e. at the end of intra-articular therapy), differences in joint functionality
could be detected between AS902330-treated dogs and placebo-treated
dogs. At week 8, mean PVF loss in the AS902330-treated group given
30mg/joint was 36.3% of baseline values, versus 47.8% in controls
(p =0.082; Mann-Whitney U test). A signiﬁcant difference in PVF loss
was also seen between AS902330 30mg and saline at week 14 (26.2%
vs 44.4%, p =0.007). The difference between groups (AS902330 30 mg
vs saline) was less pronounced at weeks 20 and 26 (35.2% vs 38.5%;
23.9% vs 33.5%, respectively). Measures of contact area followed a
similar pattern to PVF. Macroscopic gross pathology and microscopic
evaluation of cartilage using the International Cartilage Repair Society
scoring system revealed a clear reduction in the severity of cartilage
lesions in AS902330-treated dogs compared with controls at the end of
therapy (8 weeks) and after longer term follow-up (26 weeks). In addi-
tion, immunostaining for catabolic factors (e.g. matrix metalloproteinases,
inducible nitric oxide synthase) revealed a reduction in staining in the
cartilage of AS902330-treated dogs, which was maintained up to the end
of the study period (26 weeks). Systemic exposure after intra-articular
administration of AS902330 was below the lower limit of quantiﬁcation
(50 pg/mL).
Conclusions: Intra-articular injection with the anabolic agent AS902330
was shown to reduce progression of structural damage and alleviate limb
impairment in an ACL model of OA in dogs. The reduction in catabolic
parameters in the OA joint of treated animals, improved histopathology
scoring, and the improved functionality compared with saline-treated con-
trols support the hypothesis that treatment with rhFGF18 may inﬂuence
the course of OA and reduce functional impairment.
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Purpose: Osteoarthritis (OA) and rheumatoid arthritis are characterized
by a reduction of extracellular matrix and increased catabolism of colla-
gen ﬁbers and glycosaminoglycans in joints. Conventional therapy with
traditional non steroidal anti-inﬂammatory drugs (NSAIDs) and selective
COX-2 inhibitors may increase progression of cartilage degradation,
especially in long-term treatments (Mastbergen, Arthritis Res Ther 2006).
The role of nitric oxide (NO) in OA is still controversial, since it has
been recognized as a marker of inﬂammation and a possible cause
of chondrocyte loss, but also as a potent immuno-modulating factor
improving joint vascular perfusion (Hancock & Riegger-Krugh, Clin J Pain
